Journal Watch · Cellular & Molecular Immunology · 2026
TWEAK receptor (Fn14) exacerbates TNF-α-induced inflammation in rheumatoid arthritis synovial fibroblasts and influences response to anti-TNF-α therapy.
These findings reveal that TNF-α utilizes the TWEAK/Fn14 axis to induce inflammation, suggesting the potential benefits of targeting TWEAK/Fn14 as an adjunct therapy with TNF inhibitors.
TL;DR
These findings reveal that TNF-α utilizes the TWEAK/Fn14 axis to induce inflammation, suggesting the potential benefits of targeting TWEAK/Fn14 as an adjunct therapy with TNF inhibitors.
Key findings
- Gene set enrichment analysis (GSEA) revealed significant enrichment of IFN-α and IFN-γ pathway responses in the NC siRNA/TNF-α group compared with the Fn14 siRNA/TNF-α group.
- Administration of L524-0366 (10 mg/kg) intraperitoneally daily from the onset of disease ameliorated collagen antibody-induced arthritis in mice.
- These findings reveal that TNF-α utilizes the TWEAK/Fn14 axis to induce inflammation, suggesting the potential benefits of targeting TWEAK/Fn14 as an adjunct therapy with TNF inhibitors.
What they did
Furthermore, increased expression of the TWEAK receptor (Fn14) was sufficient for TNF-α to synergistically induce RANTES/CCL5 and MMP-1. In contrast, Fn14 knockdown suppressed the expression of TNF-α-induced adhesion molecules (PDPN, ICAM-1, VCAM-1, and cadherin-11) and inflammatory chemokines (MCP-1/CCL2, RANTES/CCL5, IL-8/CXCL8, and ITAC/CXCL11). Blocking Fn14 with an antagonist (L524-0366) suppressed TNF-α-induced phosphorylation of the kinases JNK, p38, and PKCδ and consequently decreased MCP-1/CCL2, RANTES/CCL5, ITAC/CXCL11, and MMP-1 production. RNA-sequencing analysis revealed >200 differentially expressed genes significantly affected by Fn14 knockdown in TNF-α-activated RASFs.
Full abstract (original)
Background: The use of TNF inhibitors (TNFis) has revolutionized the management of rheumatoid arthritis (RA) and other autoimmune conditions, but some patients remain resistant to TNFis, for which the molecular mechanisms remain elusive. Our study reveals novel molecular crosstalk between TWEAK/Fn14 and TNF-α signaling and its potential implications for therapy resistance. Elevated Fn14 expression was observed in human synovial tissues and joint homogenates from adjuvant-induced arthritis rats. Low doses of TNF-α and TWEAK synergistically induced inflammation in human RA synovial fibroblasts (RASFs).
What they did: Furthermore, increased expression of the TWEAK receptor (Fn14) was sufficient for TNF-α to synergistically induce RANTES/CCL5 and MMP-1. In contrast, Fn14 knockdown suppressed the expression of TNF-α-induced adhesion molecules (PDPN, ICAM-1, VCAM-1, and cadherin-11) and inflammatory chemokines (MCP-1/CCL2, RANTES/CCL5, IL-8/CXCL8, and ITAC/CXCL11). Blocking Fn14 with an antagonist (L524-0366) suppressed TNF-α-induced phosphorylation of the kinases JNK, p38, and PKCδ and consequently decreased MCP-1/CCL2, RANTES/CCL5, ITAC/CXCL11, and MMP-1 production. RNA-sequencing analysis revealed >200 differentially expressed genes significantly affected by Fn14 knockdown in TNF-α-activated RASFs.
Results & conclusions: Gene set enrichment analysis (GSEA) revealed significant enrichment of IFN-α and IFN-γ pathway responses in the NC siRNA/TNF-α group compared with the Fn14 siRNA/TNF-α group. Administration of L524-0366 (10 mg/kg) intraperitoneally daily from the onset of disease ameliorated collagen antibody-induced arthritis in mice. These findings reveal that TNF-α utilizes the TWEAK/Fn14 axis to induce inflammation, suggesting the potential benefits of targeting TWEAK/Fn14 as an adjunct therapy with TNF inhibitors.
Abstract © the authors / Cellular & Molecular Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41423-026-01386-y · PubMed 41611908.
Why it matters for pharma & biotech
- Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: small-molecule drug discovery
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Cellular & Molecular Immunology study find?
These findings reveal that TNF-α utilizes the TWEAK/Fn14 axis to induce inflammation, suggesting the potential benefits of targeting TWEAK/Fn14 as an adjunct therapy with TNF inhibitors.
What type of study is this?
It is a preclinical (animal / model) study, published in Cellular & Molecular Immunology in 2026. Furthermore, increased expression of the TWEAK receptor (Fn14) was sufficient for TNF-α to synergistically induce RANTES/CCL5 and MMP-1.
Where can I read the original paper?
The original is at the publisher via DOI 10.1038/s41423-026-01386-y. PubMed ID: 41611908. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/tweak-receptor-fn14-exacerbates-tnf-induced-inflammation-in-rheumatoid-a-01386y/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides